Market Newsdesk

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. (“Kyverna Therapeutics, Inc.” or the “Company”) (NASDAQ: KYTX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company’s offering documents issued in connection with its February 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=123292&wire=4

KYTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the strategy to best accomplish the IPO; (ii) the terms of the IPO, including the price at which Kyverna’s common stock would be sold; (iii) the language to be used in the Offering Documents; (iv) what disclosures about Kyverna would be made in the Offering Documents; and (v) what responses would be made to the SEC in connection with its review of the Offering Documents. As a result of those constant contacts and communications between the underwriter defendants’ representatives and Kyverna’s management, directors, and lawyers, at a minimum, the underwriterd defendants should have known of Kyverna’s undisclosed then-existing problems and plans, and the Offering Document’s materially inaccurate, misleading, and incomplete statements and omissions, as detailed herein.

WHAT’S NEXT? If you suffered a loss in Kyverna Therapeutics, Inc. during the relevant time frame, you have until February 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-inc-sued-for-securities-law-violations—contact-levi–korsinsky-before-february-7-2025-to-discuss-your-rights–kytx-302353765.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in ASP Isotopes Inc. (“ASP Isotopes Inc.” or the “Company”) (NASDAQ: ASPI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ASP Isotopes Inc. investors who were adversely affected by alleged securities fraud between October 30, 2024 and November 26, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/asp-isotopes-inc-lawsuit-submission-form?prid=123289&wire=4

ASPI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company overstated the potential effectiveness of its enrichment technology; (2) the Company overstated the development potential of its high assay low-enriched uranium facility; (3) the Company overstated the Company’s nuclear fuels operating segment results; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in ASP Isotopes Inc. during the relevant time frame, you have until February 3, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-february-3-2025-in-asp-isotopes-inc-lawsuit–aspi-302353759.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Warner Bros. Discovery, Inc. (“Warner Bros. Discovery” or the “Company”) (NASDAQ: WBD) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Warner Bros. Discovery investors who were adversely affected by alleged securities fraud between February 23, 2024 and August 7, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/warner-bros-discovery-lawsuit-submission-form?prid=123283&wire=4

WBD investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) WBD’s sports rights negotiations with the NBA were causing, or were likely to cause, the Company to significantly reevaluate its business and goodwill; (ii) WBD’s goodwill in its Networks segment had significantly deteriorated as a result of the difference between its market capitalization and book value, continued softness in certain U.S. advertising markets, and uncertainty related to affiliate and sports rights renewals, including with the NBA; (iii) the foregoing significantly increased the likelihood of WBD incurring billions of dollars in goodwill impairment charges; (iv) accordingly, defendants had overstated WBD’s overall business and financial prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Warner Bros. Discovery during the relevant time frame, you have until January 24, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-warner-bros-discovery-inc-wbd-seeking-recovery-for-investors–contact-levi–korsinsky-302353779.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Zeta Global Holdings Corp. (“Zeta Global Holdings Corp.” or the “Company”) (NYSE: ZETA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zeta Global Holdings Corp. investors who were adversely affected by alleged securities fraud between February 27, 2024 and November 13, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/zeta-global-holdings-corp-lawsuit-submission-form-2?prid=123282&wire=4

ZETA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Zeta used two-way contracts to artificially inflate financial results; (2) Zeta engaged in round trip transactions to artificially inflate financial results; (3) Zeta utilized predatory consent farms to collect user data; (4) these consent farms have driven almost the entirety of Zeta’s growth; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Zeta Global Holdings Corp. during the relevant time frame, you have until January 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-zeta-global-holdings-corp-zeta-seeking-recovery-for-investors–contact-levi–korsinsky-302353778.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in MGP Ingredients, Inc. (“MGP Ingredients, Inc.” or the “Company”) (NASDAQ: MGPI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MGP Ingredients, Inc. investors who were adversely affected by alleged securities fraud between May 4, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/mgp-ingredients-inc-lawsuit-submission-form?prid=123296&wire=4 

MGPI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the filed complaint, throughout the class period, defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about MGPI’s business, operations, and prospects. Specifically, defendants repeatedly touted a strong demand and “normal” inventory levels in brown goods (i.e., American whiskies and tequila), when in fact there had been a slowdown in consumption and oversupply in their products. Worse, defendants had assured investors that they were positioned differently than their competitors, and that this was a non-issue, because MGPI had already taken steps to mitigate the risk, when in fact it had not.

WHAT’S NEXT? If you suffered a loss in MGP Ingredients, Inc. during the relevant time frame, you have until February 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-mgp-ingredients-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline–mgpi-302353839.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Xerox Holdings Corporation (“Xerox Holdings Corporation” or the “Company”) (NASDAQ: XRX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Xerox Holdings Corporation investors who were adversely affected by alleged securities fraud between January 25, 2024 and October 28, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/xerox-holdings-corporation-lawsuit-submission-form?prid=123281&wire=4

XRX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) after a large workforce reduction, the Company’s salesforce was reorganized with new territory assignments and account coverage; (2) as a result, the Company’s salesforce productivity was disrupted; (3) as a result, the Company had a lower rate of sell-through of older products; (4) the difficulties in flushing out older product would delay the launch of key products; (5), as a result, Xerox was likely to experience lower sales and revenue; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Xerox Holdings Corporation during the relevant time frame, you have until January 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-xerox-holdings-corporation-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-january-21-2025–xrx-302353773.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. (“Cassava Sciences, Inc.” or the “Company”) (NASDAQ: SAVA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123295&wire=4

SAVA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam. Defendants’ statements included, among other things, clear confidence in simufilam’s ability to treat Alzheimer’s Disease. On November 25, 2024, Cassava released topline results for the first of its two ongoing Phase 3 studies on simufilam, the “ReThink-ALZ” study. The results indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo. Following this news, the price of Cassava’s common stock declined dramatically. From a closing market price of $26.48 per share on November 22, 2024, Cassava’s stock price fell to $4.30 per share on November 25, 2024, a decline of about 83.76% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Cassava Sciences, Inc. during the relevant time frame, you have until February 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lost-money-on-cassava-sciences-incsava-join-class-action-suit-seeking-recovery–contact-levi–korsinsky-302353828.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Celsius Holdings, Inc. (“Celsius” or the “Company”) (NASDAQ: CELH) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Celsius investors who were adversely affected by alleged securities fraud between February 29, 2024 and September 4, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/celsius-holdings-inc-lawsuit-submission-form?prid=123279&wire=4

CELH investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company deceived the investing public regarding Celsius’ prospects and business; (ii) artificially inflated the market price of Celsius common stock; (iii) allowed certain officers, directors, and insiders to generate enormous insider proceeds by selling more than 21.6 million of their personally held shares of Celsius common stock at artificially inflated prices, reaping more than $1.4 billion; and (iv) caused plaintiff and other members of the class to purchase Celsius common stock at artificially inflated prices and suffer damages as the true facts regarding Celsius were revealed.

WHAT’S NEXT? If you suffered a loss in Celsius during the relevant time frame, you have until January 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-of-celsius-holdings-inc-should-contact-levi–korsinsky-before-january-21-2025-to-discuss-your-rights–celh-302353776.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Capri Holdings Limited (“Capri Holdings” or the “Company”) (NYSE: CPRI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capri Holdings investors who were adversely affected by alleged securities fraud between August 10, 2023 and October 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=123300&wire=4

CPRI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) the accessible luxury handbag market is a distinct and well-defined market within the overall handbag market and understood as such by the Individual defendants, as well as by other Capri and Tapestry executives; (b) Capri and Tapestry maintained analogous production facilities and supply chains for their accessible luxury handbags that were distinct from the production facilities and supply chains used to manufacture luxury or mass market handbags, confirming that the accessible luxury handbag market is distinct from the mass market and luxury handbag markets; (c) Capri and Tapestry internally considered Coach and Michael Kors to be each other’s closest and most direct competitors; (d) conversely, Capri and Tapestry did not internally consider their handbag brands to be in direct competition with luxury handbags or mass market handbags; (e) a primary internal rationale for the Capri Acquisition, the acquisition of Capri by Tapestry, was to consolidate prevalent brands within the accessible luxury handbag market so as to reduce competition, increase prices, improve profit margins, and reduce consumer choice within that market; and (f) as a result of (a)-(e) above, the risk of adverse regulatory actions and/or the Capri Acquisition being blocked was materially higher than represented by defendants.

WHAT’S NEXT? If you suffered a loss in Capri Holdings during the relevant time frame, you have until February 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/capri-holdings-limited-class-action-levi–korsinsky-reminds-capri-holdings-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-february-21-2025–cpri-302353840.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Jan. 17, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=123298&wire=4

APLT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, on November 27, 2024, Applied Therapeutics issued a press release announcing that it had received a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, the Company’s lead drug candidate. The CRL indicated that the FDA completed its review of the application and determined that it was unable to approve the NDA in its current form citing deficiencies in the clinical application. Following this news, the price of Applied Therapeutics’ common stock declined dramatically. From a closing market price of $10.21 per share on November 26, 2024, Applied Therapeutics’ stock price fell to $8.57 per share on November 27, 2024 before falling further to $2.03 on November 29, 2024 and $1.75 per share on December 2, 2024, a total decline of more than 80%. After market hours on December 2, 2024, Applied Therapeutics disclosed it received a “warning letter” from the FDA referring to the clinical trial issues underlying the CRL. Applied Therapeutics’ disclosure of the “warning letter” prompted a further decline in the stock price as investors discovered the seriousness and severity of the Company’s clinical trial errors. From a closing market price of $1.75 per share on December 2, 2024, Applied Therapeutics’ stock price fell to $1.69 per share on December 3, 2024 before falling further to $1.38 per share on December 4, 2024 and $1.29 per share on December 5, 2024.

WHAT’S NEXT? If you suffered a loss in Applied Therapeutics during the relevant time frame, you have until February 18, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-levi–korsinsky-by-february-18-2025-deadline-to-join-class-action-against-applied-therapeutics-incaplt-302353837.html

SOURCE Levi & Korsinsky, LLP